GEN-MKT-18-7897-A
Jun 8, 2020 | Biopharma, Blogs, Pharma | 0 comments
There are over 7,000 genetic diseases that could potentially be cured using gene therapy. Rare metabolic diseases, autoimmune disorders, cardiovascular disease and cancers are some of the top disease classes that can be addressed with gene therapies. With over 1,000 clinical trials involving gene therapies or oligonucleotides currently in various stages, and 11 gene therapy drugs already on the market, it is clear the potential benefit to human health is profound.
This new generation of therapeutic modalities presents unprecedented technological challenges in bringing therapies to patients. These challenges have affected both the speed and ultimate cost of bringing new therapies to market, with many gene therapeutics now categorized as some of the most expensive medications currently in existence. Ultimately, there is a lack of sufficient tools as we seek faster and more accurate methods for characterizing these new classes of drugs.
Although faced with many unique challenges and still at its very early stages, the global gene therapy market is growing rapidly. As of 2019, the size of this market is estimated to be more than $1 billion, and it is expected to expand at a compound annual growth rate (CAGR) of 32%. This growth is primarily driven by an increase in the number of clinical trials, the amount of government and private funding and the number of partnerships between small biotech and large pharmaceutical companies.
This type of growth brings many opportunities, and to take advantage of them, it is crucial that you are prepared with solutions to the challenges ahead. To help you succeed, we invite you to download a copy of the gene therapy and oligonucleotide compendium. This compendium was created with you in mind, and it aims to provide you with precision analytics that will help bring your therapies to market faster.
The compendium includes:
Download now >
Developing an analytical method can be one of the most rewarding jobs an analytical scientist can do, but it can also be one of the most complex and frustrating. To help guide your practical experiments and thought processes we spoke to Kean Woodmansey to benefit from his experience.
As analytical organizations grow, there is an even greater need to train scientists and operators more consistently to meet tight deadlines, handle increasing samples, and meet data quality expectations. A high rate of employee turnover also affects the productivity of labs worldwide. Consistent training helps today’s labs stay competitive, whether the goal is sample throughput, therapeutic development, or publication.
A few years ago, I was plotting along in my analytical job and keeping up-to-date with residue regulations took a considerable amount of time, but it was always manageable. Nowadays, we have PFAS.
Posted by
You must be logged in to post a comment.
Share this post with your network